BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 31554227)

  • 1. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
    Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computer-Aided Design of Orally Bioavailable Pyrrolidine Carboxamide Inhibitors of Enoyl-Acyl Carrier Protein Reductase of Mycobacterium tuberculosis with Favorable Pharmacokinetic Profiles.
    Kouassi AF; Kone M; Keita M; Esmel A; Megnassan E; N'Guessan YT; Frecer V; Miertus S
    Int J Mol Sci; 2015 Dec; 16(12):29744-71. PubMed ID: 26703572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtually Designed Triclosan-Based Inhibitors of Enoyl-Acyl Carrier Protein Reductase of Mycobacterium tuberculosis and of Plasmodium falciparum.
    Owono Owono LC; Ntie-Kang F; Keita M; Megnassan E; Frecer V; Miertus S
    Mol Inform; 2015 May; 34(5):292-307. PubMed ID: 27490275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Based Design and Pharmacophore-Based Virtual Screening of Combinatorial Library of Triclosan Analogues Active against Enoyl-Acyl Carrier Protein Reductase of
    Bieri C; Esmel A; Keita M; Owono LCO; Dali B; Megnassan E; Miertus S; Frecer V
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore mapping, molecular docking, chemical synthesis of some novel pyrrolyl benzamide derivatives and evaluation of their inhibitory activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis.
    Joshi SD; Dixit SR; Basha J; Kulkarni VH; Aminabhavi TM; Nadagouda MN; Lherbet C
    Bioorg Chem; 2018 Dec; 81():440-453. PubMed ID: 30223149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple receptor conformers based molecular docking study of fluorine enhanced ethionamide with mycobacterium enoyl ACP reductase (InhA).
    Khan AM; Shawon J; Halim MA
    J Mol Graph Model; 2017 Oct; 77():386-398. PubMed ID: 28957755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-trans Enoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity.
    Guardia A; Gulten G; Fernandez R; Gómez J; Wang F; Convery M; Blanco D; Martínez M; Pérez-Herrán E; Alonso M; Ortega F; Rullás J; Calvo D; Mata L; Young R; Sacchettini JC; Mendoza-Losana A; Remuiñán M; Ballell Pages L; Castro-Pichel J
    ChemMedChem; 2016 Apr; 11(7):687-701. PubMed ID: 26934341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.
    He X; Alian A; Ortiz de Montellano PR
    Bioorg Med Chem; 2007 Nov; 15(21):6649-58. PubMed ID: 17723305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of New and Potent InhA Inhibitors as Antituberculosis Agents: Structure-Based Virtual Screening Validated by Biological Assays and X-ray Crystallography.
    Kamsri P; Hanwarinroj C; Phusi N; Pornprom T; Chayajarus K; Punkvang A; Suttipanta N; Srimanote P; Suttisintong K; Songsiriritthigul C; Saparpakorn P; Hannongbua S; Rattanabunyong S; Seetaha S; Choowongkomon K; Sureram S; Kittakoop P; Hongmanee P; Santanirand P; Chen Z; Zhu W; Blood RA; Takebayashi Y; Hinchliffe P; Mulholland AJ; Spencer J; Pungpo P
    J Chem Inf Model; 2020 Jan; 60(1):226-234. PubMed ID: 31820972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Aryl-1,4-Dihydropyridines as Potential Enoyl-Acyl Carrier Protein Reductase Inhibitors: Antitubercular Activity and Molecular Docking Study.
    Venugopala KN; Deb PK; Pillay M; Chopra D; Chandrashekharappa S; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Kandeel M; Venugopala R; Mohanlall V
    Curr Top Med Chem; 2021; 21(4):295-306. PubMed ID: 33138763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
    Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of a novel class of potent inhibitors of InhA, the enoyl acyl carrier protein reductase from Mycobacterium tuberculosis: a computer modelling approach.
    Subba Rao G; Vijayakrishnan R; Kumar M
    Chem Biol Drug Des; 2008 Nov; 72(5):444-9. PubMed ID: 19012578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of the novel inhibitor for Mycobacterium enoyl-acyl carrier protein reductase (InhA): a structure-activity relationship study of KES4 assisted by in silico structure-based drug screening.
    Taira J; Umei T; Inoue K; Kitamura M; Berenger F; Sacchettini JC; Sakamoto H; Aoki S
    J Antibiot (Tokyo); 2020 Jun; 73(6):372-381. PubMed ID: 32152525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural modification of a novel inhibitor for mycobacterium enoyl-acyl carrier protein reductase assisted by
    Taira J; Nagano T; Kitamura M; Yamaguchi M; Sakamoto H; Aoki S
    Int J Mycobacteriol; 2020; 9(1):12-17. PubMed ID: 32474482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach.
    Kumar UC; Bvs SK; Mahmood S; D S; Kumar-Sahu P; Pulakanam S; Ballell L; Alvarez-Gomez D; Malik S; Jarp S
    Future Med Chem; 2013 Mar; 5(3):249-59. PubMed ID: 23464516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors: A combined in-silico and in-vitro analysis.
    Lone MY; Athar M; Gupta VK; Jha PC
    J Mol Graph Model; 2017 Sep; 76():172-180. PubMed ID: 28734205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D-QSAR studies of arylcarboxamides with inhibitory activity on InhA using pharmacophore-based alignment.
    Lu XY; Chen YD; You QD
    Chem Biol Drug Des; 2010 Feb; 75(2):195-203. PubMed ID: 20028393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
    Saharan VD; Mahajan SS
    Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors.
    Tripathy S; Azam MA; Jupudi S; Sahu SK
    J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virtual screening and synthesis of novel antitubercular agents through interaction-based pharmacophore and molecular docking studies.
    Bhattarai D; Muddassar M; Jang JW; Hong SK; Kim EE; Oh T; Cho SN; Pae AN; Keum G
    Curr Comput Aided Drug Des; 2014; 10(4):383-92. PubMed ID: 25872944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.